Navigation Links
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
Date:5/14/2009

he demographic and blinded safety data from the ongoing Phase III study, the LUX-Lung 1 trial, will be presented at ASCO for the first time.(5)

The LUX-Lung 1 study addresses a critical need for treatment options for NSCLC patients after failure with a second-line or third-line reversible EGFR inhibitor (i.e., erlotinib or gefitinib). This study recently moved from Phase IIb into Phase III.(5)

"The LUX-Lung 1 study is important as it investigates BIBW 2992 in a group of patients for whom there are no other approved treatment options. These are patients who have already been through standard first-line or second-line chemotherapy and then received treatment with an EGFR TKI. The LUX-Lung 1 study will evaluate whether BIBW 2992 will extend the lives of these cancer patients,"(5) said Dr. Haehl.

First Presentation of Phase II Data on BIBF 1120 in Ovarian Cancer

Data from a Phase II study of BIBF 1120 in patients with ovarian cancer who responded to at least second-line chemotherapy will be presented at ASCO in Orlando. The study showed a potential delay in disease progression: With BIBF 1120 the median time to RECIST progression was 4.8, versus 2.8 for placebo.(11) BIBF 1120 is an oral compound that works by simultaneously inhibiting vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs) and fibroblast growth factor receptors (FGFRs) -- all factors which are involved in the formation of blood vessels, a process known as angiogenesis.(12,13).

"There is a great need for more effective and well tolerated treatment options for women with ovarian cancer.(14) We have a growing body of evidence that anti-angiogenic agents may represent an important treatment approach for this disease,"(15,16,17) commented Prof. Jonathan A. Ledermann, MD, Professor of Medical Oncology & Director at the Cancer Research UK & UCL Cancer Trials
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) ... November 30, 2013, compared to sales of $2,202,000 for the ... again, this quarter has also shown growth over the preceding ... quarter of this fiscal year. Markets that experienced sales increases ...
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced ... its strategic advisor as it pursues various avenues aimed at ... ANA598, in development for the treatment of hepatitis C.  Anadys ... conclusion of 12 weeks of dosing ANA598 in combination with ...
... Inc. (OTC Bulletin Board: HEWA), a leading retail mail-order ... (VIPPS(CM)) accreditation from The National Association of Boards of Pharmacy (NABP). ... accredited in the United States .   , ... According to NABP which has ...
Cached Medicine Technology:Anadys Retains Lazard as Strategic Advisor 2Anadys Retains Lazard as Strategic Advisor 3Anadys Retains Lazard as Strategic Advisor 4Anadys Retains Lazard as Strategic Advisor 5HealthWarehouse.com Receives VIPPS Accreditation From The National Association of Boards of Pharmacy 2
(Date:7/10/2014)... In his latest blog post at ... facility CEO Per Wickstrom has listed 5 ways to ... confirm an appointment, get information or sometimes even just ... being annoying is a skill that most people don’t ... to keep the dialogue moving without coming across as ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
(Date:7/10/2014)... City, CA (PRWEB) July 10, 2014 ... announced the latest results of the 4th “Trending ... "Source-to-Pay” suite model. , Every day multinational ... data, contracts, expense forms etc. To meet this ... "Source-to-Pay" (S2P) suites which can be defined as ...
(Date:7/10/2014)... widespread across the United States, due in large to ... of clinical data that will become available for research ... experts in healthcare have become increasingly focused on clinical ... purpose of gleaning insights that have the potential to ... that is known as big data. ...
(Date:7/10/2014)... professional football players who have shoulder stabilization surgery are ... finds. Shoulder instability is a common injury among ... to fix the problem has been unclear, the study ... who had shoulder stabilization surgery. Ninety percent of those ... as playing in at least one regular season game. ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Shoulder Surgery Gets NFL Players Back in the Game 2
... came to the Brampton, Ont., Tim Horton's location are being ... ,According to health officials in Peel Region, an employee ... tested positive for hepatitis A. ,Peel's associate medical ... that the risk of transmission is low. ,However De Villa ...
... Egger, of the University of Bern in Switzerland, AIDS ... side effects// due the drug. ,There is ... It been ten years since the antiretroviral (ARVs) have ... and drawbacks. Scientists say that the combinations of drugs ...
... fibers could stretch to three times its length before going ... to six times// their original length before breaking. ... from a soluble protein, fibrinogen. When an injury occurs ... a mesh, which dries and hardens, so that bleeding stops. ...
... been a storm brewing over a particular brand of milk, ... on the warfarin drug. Fonterra, the company// that is manufacturing ... were well aware of the impending risks of the milk ... to disclose the warning on the product. ...
... who was denied admission to a medical college here because ... disability, has urged President// A.P.J. Abdul Kalam to intervene. ... of the state joint entrance examination, was denied admission to ... examining her again despite the chief district medical officer R.C. ...
... popular supermarket chains have announced that they would completely avoid ... ,Trans fat was recently in the news as it increased ... thought to cause cancers among some people. The supermarket chains ... amounts of hydrogenated oil pose great threat and affected the ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: